- Product Details
- Description
- Additional information
- More Offers
Description
Background Information:
ASP3026 is A potent and selective ALK ( Anaplastic Lymphoma Kinase) inhibitor. It is more selective than Crizotinib in a kinase panel, and showed potent anti-tumor activity in an EML4-ALK driven tumor model with gatekeeper mutation while Crizotinib was ineffective even at 100 mg/gk qd (ref 1). It is currently in clinical trials.
Reference:
1. S. Kuromitsu, et al., Abstract A227: Antitumor activities of ASP3026 against EML4-ALK-dependent tumor models, Mol Cancer Ther, Nov. 2011; Volume 10, Issue 11, Supplement 1.
2. Suraj K. George, et al, The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model, Oncotarget, Vol. 5, No. 14, p5750-5763.
APIM050084: ASP3026
CAS No.: 1097917-15-1.
Molecular Formula: C29H40N8O3S.
Molecular Weight: 580.74.
Purity: >99% (HPLC at 214 and 254 nm).
QC: HPLC-MS, 1HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO and water with 2 eq. of acid.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
Additional information
| Ship from Country | USA |
|---|---|
| Size | 10 mg, 100 mg, 200 mg, 5 mg, 50 mg |
